What is it about?
Several studies revealed the beneficial role of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in experimental animal models of arthritis. The newly approved ARBs, such as telmisartan and azilsartan, demonstrated potent anti-inflammatory activity in animal models through mechanisms not related to RAS blockade
Featured Image
Why is it important?
For the first time, we reported that azilsartan may improve the effects of methotrexate on the clinical scores and certain inflammatory biomarkers of patients with active RA.
Perspectives
Publishing these data was a great pleasure as it has co-authors with whom I have had long-standing collaborations. These data also highlighted the issue of the important outcomes of blocking RAS with the new generation of ARBs, like Azilsartan, to get a potent anti-inflammatory effect. This approach may have many clinical applications for the treatment of inflammatory disorders.
Professor Saad Abdulrahman Hussain
Al-Rafidain University College, Faculty of Pharmacy, Baghdad, Iraq
Read the Original
This page is a summary of: Azilsartan as “Add-On” Treatment with Methotrexate Improves the Disease Activity of Rheumatoid Arthritis, BioMed Research International, January 2018, Hindawi Publishing Corporation,
DOI: 10.1155/2018/7164291.
You can read the full text:
Contributors
The following have contributed to this page
